WGU D116 Advanced Pharmacology
Enhanced Objective Assessment Study Guide — 2026/2027
Original educational companion: expanded from the publicly visible structure and topic coverage of the referenced Stuvia listing. It
is not a copy of the paid/locked document and does not reproduce proprietary exam questions.
The referenced listing is a 183-page exam-elaboration document titled “WGU D116 Advanced Pharmacology OA Exam
2026/2027 Actual Exam - 500 Questions with Detailed Rationales | 100% Verified Graded A+ Pass Guaranteed - A+ Graded,”
written for 2025/2026. Its public preview begins with pharmacokinetics/pharmacodynamics and shows questions on first-pass
metabolism, therapeutic index, CYP3A4, protein binding, agonists/antagonists, half-life, routes, bioavailability, interactions, and
elimination. ■cite■turn0view0■
Study note: medication choices and dosing can depend on indication, organ function, age, pregnancy, interactions, and current
guidelines. Use your official WGU materials and current clinical references for patient-care decisions.
How to Use This Guide
• First pass: master mechanisms and “why,” not isolated drug names.
• Second pass: use the comparison tables and exam traps.
• Third pass: answer the original practice questions without looking at the rationales.
• Final pass: rehearse the 60-second clinical pharmacology framework at the end.
High-Yield Master Map
Domain What to recognize Common exam move
PK / ADME Absorption, distribution, metabolism, excretion Predict concentration, onset, duration, accumulation
PD Receptors, agonists, antagonists, dose-response Predict effect and receptor competition
Safety Therapeutic index, adverse effects, contraindications Choose safest action before treating the symptom
Interactions CYP inhibition/induction, additive effects Predict ↑ or ↓ exposure
CV/Renal RAAS, antihypertensives, anticoagulants, diuretics Link mechanism to BP, K+, renal function, bleeding
Endocrine Insulin, thyroid, diabetes, steroids Match physiology, monitoring, and adverse effects
CNS/Psych Antidepressants, antipsychotics, sedatives, stimulants Recognize toxicity and syndrome patterns
Anti-infectives Mechanism, spectrum, resistance, monitoring Match organism/drug while checking safety
Special populations Older adults, pregnancy, renal/hepatic impairment Adjust risk, clearance, and monitoring
1. Pharmacokinetics & Pharmacodynamics Fundamentals
Q: PK asks “what the body does to the drug.” The four core processes are absorption, distribution, metabolism, and excretion
(ADME).
Answer: The route of administration, blood flow, membrane properties, protein binding, hepatic metabolism, and renal
clearance all influence exposure.
Q: Bioavailability is the fraction of an administered dose reaching systemic circulation unchanged. IV administration is the
reference for 100% bioavailability.
Answer: Oral drugs can lose exposure through incomplete absorption and first-pass metabolism.
Q: Half-life is the time required for plasma concentration to fall by 50% during the relevant elimination phase.
, Answer: With first-order elimination, about 4–5 half-lives are needed to approach steady state; a loading dose can reach a
target concentration faster when appropriate.
Q: Competitive antagonists reversibly compete at the receptor site; increasing agonist concentration can overcome the
blockade.
Answer: Noncompetitive or irreversible antagonism reduces the achievable maximal response rather than simply shifting the
competition.
Exam lens: Convert the stem into four items: indication → mechanism → patient-specific risk → monitoring. The best answer
usually satisfies all four.
2. Autonomic & Central Nervous System Pharmacology
Q: Sympathetic stimulation generally increases heart rate and contractility, dilates bronchi, and redirects blood flow;
parasympathetic activity promotes rest-and-digest functions.
Answer: Always connect receptor subtype to organ effect before choosing a drug.
Q: Anticholinergic effects include dry mouth, blurred vision, constipation, urinary retention, and tachycardia.
Answer: Older adults are particularly vulnerable to cumulative anticholinergic burden.
Q: Sedative drugs can impair cognition, coordination, and respiratory drive.
Answer: Combining CNS depressants can produce additive or synergistic toxicity; assess the full medication list rather than
one drug alone.
Exam lens: Convert the stem into four items: indication → mechanism → patient-specific risk → monitoring. The best answer
usually satisfies all four.
3. Cardiovascular & Renal Pharmacology
Q: RAAS blockade can lower blood pressure and reduce maladaptive remodeling, but renal function and potassium require
attention.
Answer: ACE inhibitors commonly cause cough and can cause hyperkalemia and angioedema; ARBs avoid the
bradykinin-related cough mechanism.
Q: Loop diuretics are potent natriuretic agents; thiazides are commonly used for hypertension; potassium-sparing agents can
raise potassium.
Answer: The exam often tests mechanism → electrolyte change → monitoring.
Q: Anticoagulants reduce clot formation but do not dissolve an established thrombus instantly.
Answer: Bleeding risk, renal function, interacting medicines, and indication determine the safest regimen.
Exam lens: Convert the stem into four items: indication → mechanism → patient-specific risk → monitoring. The best answer
usually satisfies all four.
4. Respiratory & Allergy Pharmacology
Q: Short-acting bronchodilators provide rapid symptom relief; inhaled corticosteroids reduce airway inflammation and are
controller therapy.
Answer: A rescue inhaler is not a substitute for appropriate long-term anti-inflammatory management when persistent
disease is present.
Q: Antihistamines reduce histamine-mediated symptoms, but first-generation agents can cause sedation and anticholinergic
effects.
Answer: Driving risk and polypharmacy matter in medication counseling.
Enhanced Objective Assessment Study Guide — 2026/2027
Original educational companion: expanded from the publicly visible structure and topic coverage of the referenced Stuvia listing. It
is not a copy of the paid/locked document and does not reproduce proprietary exam questions.
The referenced listing is a 183-page exam-elaboration document titled “WGU D116 Advanced Pharmacology OA Exam
2026/2027 Actual Exam - 500 Questions with Detailed Rationales | 100% Verified Graded A+ Pass Guaranteed - A+ Graded,”
written for 2025/2026. Its public preview begins with pharmacokinetics/pharmacodynamics and shows questions on first-pass
metabolism, therapeutic index, CYP3A4, protein binding, agonists/antagonists, half-life, routes, bioavailability, interactions, and
elimination. ■cite■turn0view0■
Study note: medication choices and dosing can depend on indication, organ function, age, pregnancy, interactions, and current
guidelines. Use your official WGU materials and current clinical references for patient-care decisions.
How to Use This Guide
• First pass: master mechanisms and “why,” not isolated drug names.
• Second pass: use the comparison tables and exam traps.
• Third pass: answer the original practice questions without looking at the rationales.
• Final pass: rehearse the 60-second clinical pharmacology framework at the end.
High-Yield Master Map
Domain What to recognize Common exam move
PK / ADME Absorption, distribution, metabolism, excretion Predict concentration, onset, duration, accumulation
PD Receptors, agonists, antagonists, dose-response Predict effect and receptor competition
Safety Therapeutic index, adverse effects, contraindications Choose safest action before treating the symptom
Interactions CYP inhibition/induction, additive effects Predict ↑ or ↓ exposure
CV/Renal RAAS, antihypertensives, anticoagulants, diuretics Link mechanism to BP, K+, renal function, bleeding
Endocrine Insulin, thyroid, diabetes, steroids Match physiology, monitoring, and adverse effects
CNS/Psych Antidepressants, antipsychotics, sedatives, stimulants Recognize toxicity and syndrome patterns
Anti-infectives Mechanism, spectrum, resistance, monitoring Match organism/drug while checking safety
Special populations Older adults, pregnancy, renal/hepatic impairment Adjust risk, clearance, and monitoring
1. Pharmacokinetics & Pharmacodynamics Fundamentals
Q: PK asks “what the body does to the drug.” The four core processes are absorption, distribution, metabolism, and excretion
(ADME).
Answer: The route of administration, blood flow, membrane properties, protein binding, hepatic metabolism, and renal
clearance all influence exposure.
Q: Bioavailability is the fraction of an administered dose reaching systemic circulation unchanged. IV administration is the
reference for 100% bioavailability.
Answer: Oral drugs can lose exposure through incomplete absorption and first-pass metabolism.
Q: Half-life is the time required for plasma concentration to fall by 50% during the relevant elimination phase.
, Answer: With first-order elimination, about 4–5 half-lives are needed to approach steady state; a loading dose can reach a
target concentration faster when appropriate.
Q: Competitive antagonists reversibly compete at the receptor site; increasing agonist concentration can overcome the
blockade.
Answer: Noncompetitive or irreversible antagonism reduces the achievable maximal response rather than simply shifting the
competition.
Exam lens: Convert the stem into four items: indication → mechanism → patient-specific risk → monitoring. The best answer
usually satisfies all four.
2. Autonomic & Central Nervous System Pharmacology
Q: Sympathetic stimulation generally increases heart rate and contractility, dilates bronchi, and redirects blood flow;
parasympathetic activity promotes rest-and-digest functions.
Answer: Always connect receptor subtype to organ effect before choosing a drug.
Q: Anticholinergic effects include dry mouth, blurred vision, constipation, urinary retention, and tachycardia.
Answer: Older adults are particularly vulnerable to cumulative anticholinergic burden.
Q: Sedative drugs can impair cognition, coordination, and respiratory drive.
Answer: Combining CNS depressants can produce additive or synergistic toxicity; assess the full medication list rather than
one drug alone.
Exam lens: Convert the stem into four items: indication → mechanism → patient-specific risk → monitoring. The best answer
usually satisfies all four.
3. Cardiovascular & Renal Pharmacology
Q: RAAS blockade can lower blood pressure and reduce maladaptive remodeling, but renal function and potassium require
attention.
Answer: ACE inhibitors commonly cause cough and can cause hyperkalemia and angioedema; ARBs avoid the
bradykinin-related cough mechanism.
Q: Loop diuretics are potent natriuretic agents; thiazides are commonly used for hypertension; potassium-sparing agents can
raise potassium.
Answer: The exam often tests mechanism → electrolyte change → monitoring.
Q: Anticoagulants reduce clot formation but do not dissolve an established thrombus instantly.
Answer: Bleeding risk, renal function, interacting medicines, and indication determine the safest regimen.
Exam lens: Convert the stem into four items: indication → mechanism → patient-specific risk → monitoring. The best answer
usually satisfies all four.
4. Respiratory & Allergy Pharmacology
Q: Short-acting bronchodilators provide rapid symptom relief; inhaled corticosteroids reduce airway inflammation and are
controller therapy.
Answer: A rescue inhaler is not a substitute for appropriate long-term anti-inflammatory management when persistent
disease is present.
Q: Antihistamines reduce histamine-mediated symptoms, but first-generation agents can cause sedation and anticholinergic
effects.
Answer: Driving risk and polypharmacy matter in medication counseling.
